Re: >>> I wonder if the analysis of the GTOP trial has a few analysis wrinkles that were spelled out in the SPA but not revealed to the public? <<<
That seems to me to be the rule rather than the exception regarding SPA details. I think companies could be a little more forthcoming to investors about these issues without compromising proprietary info. I think the more open a company is about such matters , the less likely it is that they're running a scam.
>>> Perhaps a post-hoc adjustment or two that the FDA allowed in exchange for a more stringent p-value? <<<
Probably as good a bet as any. I'd like to know the definitive answer , even though I have no position nor any particular interest in GTOP.
Market Data 
Markets 
AI
